Jaknat 5mg, also known as Tofacitinib 5mg, is a generic Janus kinases (JAKs) inhibitor that has been approved for the treatment of various medical conditions, including:
Moderately to severely active rheumatoid arthritis in adult patients who have not responded well to methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs). Jaknat 5mg can be used alone or in combination with methotrexate or other non-biologic DMARDs. However, it is not recommended to be used together with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine.
Active psoriatic arthritis in adult patients who have not responded well to methotrexate or other DMARDs. Similar to its use in rheumatoid arthritis, Jaknat 5mg can be used alone or in combination with other non-biologic DMARDs, but not with biologic DMARDs or potent immunosuppressants like azathioprine and cyclosporine.
Moderately to severely active ulcerative colitis (UC) in adult patients who have not responded well to TNF blockers or are intolerant to them. However, using Jaknat 5mg in combination with biologic therapies for UC or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
Active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients aged two years and older. The oral solution of Tofacitinib is indicated for this use. But, it should not be used together with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine.
For Rheumatoid Arthritis, the recommended dose of Tofacitinib is 5 mg twice daily or 11 mg once daily. In patients with moderate to severe renal impairment or moderate hepatic impairment, the recommended dose is 5 mg once daily. However, the use of Tofacitinib 11mg is not recommended in patients with severe hepatic impairment. Some studies suggest that turmeric supplements may help with arthritis and joint pain relief.
For Psoriatic Arthritis, the recommended dose of Tofacitinib is 5 mg twice daily in combination with nonbiologic DMARDs or 11 mg once daily in combination with nonbiologic DMARDs. In patients with moderate to severe renal impairment or moderate hepatic impairment, the recommended dose is 5 mg once daily. However, the use of Tofacitinib 11mg is not recommended in patients with severe hepatic impairment.
For Ulcerative Colitis, the recommended dose of Tofacitinib is 10 mg twice daily or 22 mg once daily for 8 weeks for induction. After 8 weeks, patients should be evaluated and transitioned to maintenance therapy based on their therapeutic response. If necessary, Tofacitinib can be continued at 10 mg twice daily or 22 mg once daily for a maximum of 16 weeks. If an adequate therapeutic response is not achieved after 16 weeks, Tofacitinib should be discontinued. For maintenance therapy, the recommended dose is 5 mg twice daily or 11 mg once daily. If a patient experiences a loss of response during maintenance treatment, Tofacitinib 10 mg twice daily or 22 mg once daily may be considered, but only for the shortest duration possible, with careful consideration of the benefits and risks for the individual patient. The lowest effective dose needed to maintain a response should be used. Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment.
For Polyarticular Course Juvenile Idiopathic Arthritis, the recommended dose of Tofacitinib Oral Solution is 5 mg twice daily or weight-based equivalent twice daily. Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment. Please see the full prescribing information for further details.
Tofacitinib Side Effects：
TOFACITINIB 5MG/11MG is a medication that affects the immune system and may decrease the ability of your body to fight infections, including serious ones like tuberculosis, bacterial, fungal or viral infections that can spread throughout the body. Some people have even died from these infections. It is important that your healthcare provider tests you for tuberculosis before starting and during treatment with TOFACITINIB 5MG/11MG, and monitors you closely for signs of infection.
You should not take TOFACITINIB 5MG/11MG if you currently have any infection, unless your healthcare provider says it is safe to do so. Before starting treatment, inform your healthcare provider if you have a history of infections, diabetes, chronic lung disease, HIV, weak immune system, or if you live in or have traveled to areas where fungal infections are common. Additionally, if you experience symptoms of infection such as fever, cough, or diarrhea, contact your healthcare provider immediately.
Taking TOFACITINIB 5MG/11MG may increase the risk of certain types of cancer, including lymphoma and skin cancer. Therefore, it is important to tell your healthcare provider if you have ever had cancer. Additionally, some people who have taken TOFACITINIB with certain other medicines have experienced a problem with white blood cells growing out of control.
Taking TOFACITINIB 5MG/11MG may also increase the risk of tears in the stomach or intestines, especially in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Inform your healthcare provider if you have had diverticulitis or ulcers in your stomach or intestines. Contact your healthcare provider immediately if you experience fever and stomach-area pain that does not go away, or a change in bowel habits.
Your healthcare provider should regularly check certain blood tests, including lymphocyte, neutrophil, and red blood cell counts, as well as liver tests, while you are taking TOFACITINIB 5MG/11MG. If any of these test results are abnormal, your healthcare provider may temporarily stop treatment. You may also need to have your blood cholesterol levels checked regularly while taking TOFACITINIB 5MG/11MG. Normal cholesterol levels are important for good heart health.
Tofacitinib cost in India：
Buy tofacitinib online from India online pharmacy is 8% of the brand Tofacitinib.
To obtain further details on prescribing, please request the "FDA Prescribing Information" from our customer service.
|Don't take the drug without consulting a qualified doctor or physician
|Follow the doctor's advice
|Delivery & Returns